181 related articles for article (PubMed ID: 20175802)
1. Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Kagaya H; Saito M; Inoue T; Ohkubo T; Habuchi T; Suzuki T
J Clin Pharm Ther; 2009 Dec; 34(6):683-92. PubMed ID: 20175802
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
3. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
4. Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.
Wang L; Zhao L; Zhang D; Chen JZ; Xue JL
Chin Med J (Engl); 2012 Jun; 125(12):2200-4. PubMed ID: 22884153
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration.
Baek IH; Lee BY; Lee ES; Kwon KI
Drug Res (Stuttg); 2013 Jul; 63(7):357-61. PubMed ID: 23539423
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.
Hong SJ; Shim WJ; Choi JI; Joo HJ; Shin SY; Park SM; Lim SY; Lim DS
Am J Cardiol; 2007 Dec; 100(11):1625-9. PubMed ID: 18036359
[TBL] [Abstract][Full Text] [Related]
8. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
Bhuiyan MA; Hossain M; Nakamura T; Ozaki M; Nagatomo T
J Pharmacol Sci; 2010; 112(4):459-62. PubMed ID: 20308802
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
10. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Kagaya H; Inoue K; Miura M; Satoh S; Saito M; Tada H; Habuchi T; Suzuki T
Eur J Clin Pharmacol; 2007 Mar; 63(3):279-88. PubMed ID: 17211619
[TBL] [Abstract][Full Text] [Related]
11. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
[TBL] [Abstract][Full Text] [Related]
12. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
13. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
15. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
17. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
Khan AH; Imig JD
Am J Hypertens; 2011 Jul; 24(7):816-21. PubMed ID: 21415842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
